3 days ago
Gilead Sciences (NASDAQ: GILD) has no major concerns about its HIV franchise until the next decade. That hasn't kept the pharmaceutical company from preparing for the loss of exclusivity for its legacy HIV therapies. Gilead has spent heavily on its pipeline, and that's paying off.
The company has received three Food and Drug (FDA) approvals over the past four months, and not coincidentally, its shares are up more than 21% so far this year, nearly doubling the S&P 500 index's rise. The most recent approval was on Aug. 27 for Bixlenvo as a daily pill to treat virologically suppressed adults with HIV.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
Prior to that, on June 24, Trodelvy received two new approvals to treat triple-negative breast cancer. On May 22, the FDA granted Hepcludex accelerated approval to treat chronic hepatitis delta virus (HDV) infection in adults without cirrhosis or with compensated cirrhosis.
Despite the stock's rise and all the good news on the pipeline front, Gilead may be underrated. There are three reasons why I feel that is the case.
#gilead #NVIDIA #three
The company has received three Food and Drug (FDA) approvals over the past four months, and not coincidentally, its shares are up more than 21% so far this year, nearly doubling the S&P 500 index's rise. The most recent approval was on Aug. 27 for Bixlenvo as a daily pill to treat virologically suppressed adults with HIV.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
Prior to that, on June 24, Trodelvy received two new approvals to treat triple-negative breast cancer. On May 22, the FDA granted Hepcludex accelerated approval to treat chronic hepatitis delta virus (HDV) infection in adults without cirrhosis or with compensated cirrhosis.
Despite the stock's rise and all the good news on the pipeline front, Gilead may be underrated. There are three reasons why I feel that is the case.
#gilead #NVIDIA #three
4 days ago
Foster City, California-based Gilead Sciences, Inc. (GILD) discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States and internationally. The company has a market cap of $185.9 billion and provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and Yeztugo for the treatment of HIV-1 infection in patients, as well as other related drugs.
Companies with a market cap of $10 billion or more are typically referred to as "large-cap stocks." GILD fits perfectly into that category, with its market cap exceeding this threshold and reflecting its substantial size and influence in the general drug manufacturers industry.
Nvidia CEO Jensen Huang Says His $3.5 Billion MediaTek Deal Is 'Not Circular' Because 'They Do Their Own Business'
Strategy's Strategy Appears to Have Failed, and the Outlook of MSTR Stock Is Unfavorable
A Potential ******* eX Deal Could Meaningfully Accelerate Growth for Technip Stock
#gild #deal #Stock #sciences
Companies with a market cap of $10 billion or more are typically referred to as "large-cap stocks." GILD fits perfectly into that category, with its market cap exceeding this threshold and reflecting its substantial size and influence in the general drug manufacturers industry.
Nvidia CEO Jensen Huang Says His $3.5 Billion MediaTek Deal Is 'Not Circular' Because 'They Do Their Own Business'
Strategy's Strategy Appears to Have Failed, and the Outlook of MSTR Stock Is Unfavorable
A Potential ******* eX Deal Could Meaningfully Accelerate Growth for Technip Stock
#gild #deal #Stock #sciences
7 days ago
By Mike Sheikh
Cocrystal Pharma (NASDAQ: COCP) may look like another undercapitalized, clinical-stage biotech searching for its niche, and in need of a rescue, but there is more to this story than what meets the eye. Investors glancing at the stock chart may miss the signs of a strategic reset orchestrated by biotech legends, and miss this unique opportunity.
COCP is not a company that lacks science or researchers. It has a drug discovery platform technology capable of delivering broad spectrum antivirals on demand for high value diseases that include norovirus, influenza, coronaviruses, and hepatitis C. If you had to point to something they were lacking then the missing "it factor" was a clear strategic vision. They needed an operator and a commercialization guru capable of aligning the board to his vision and raising the capital they needed on favorable terms to turn a platform technology into an enterprise.
The appointment of James Sapirstein was a transformative moment for the company.
Sapirstein is a high powered biotech exec with an impeccable pedigree. He's not an eager early-career operator looking to make a name for himself. Investors need to realize he joined after decades of experience in commercial pharmaceutical leadership, antiviral development, product launches, and business development. From his bio we learned that he has participated in or led 23 product launches and has driven numerous business-development transactions. His résumé includes founding CEO of Tobira Therapeutics, CEO of Contravir Pharmaceuticals (Hepion Pharmaceuticals, Inc. NASDAQ: HEPA), executive leadership at Serono Laboratories, senior commercial roles at Gilead Sciences (NASDAQ: GILD), and international marketing leadership in Bristol Myers Squibb's (NYSE:BMY) infectious-disease division.
#NASDAQ #Biotech
Cocrystal Pharma (NASDAQ: COCP) may look like another undercapitalized, clinical-stage biotech searching for its niche, and in need of a rescue, but there is more to this story than what meets the eye. Investors glancing at the stock chart may miss the signs of a strategic reset orchestrated by biotech legends, and miss this unique opportunity.
COCP is not a company that lacks science or researchers. It has a drug discovery platform technology capable of delivering broad spectrum antivirals on demand for high value diseases that include norovirus, influenza, coronaviruses, and hepatitis C. If you had to point to something they were lacking then the missing "it factor" was a clear strategic vision. They needed an operator and a commercialization guru capable of aligning the board to his vision and raising the capital they needed on favorable terms to turn a platform technology into an enterprise.
The appointment of James Sapirstein was a transformative moment for the company.
Sapirstein is a high powered biotech exec with an impeccable pedigree. He's not an eager early-career operator looking to make a name for himself. Investors need to realize he joined after decades of experience in commercial pharmaceutical leadership, antiviral development, product launches, and business development. From his bio we learned that he has participated in or led 23 product launches and has driven numerous business-development transactions. His résumé includes founding CEO of Tobira Therapeutics, CEO of Contravir Pharmaceuticals (Hepion Pharmaceuticals, Inc. NASDAQ: HEPA), executive leadership at Serono Laboratories, senior commercial roles at Gilead Sciences (NASDAQ: GILD), and international marketing leadership in Bristol Myers Squibb's (NYSE:BMY) infectious-disease division.
#NASDAQ #Biotech
11 days ago
There were a few eyepopping performances put together by Marion-area football players during Week 2 action Aug. 28.
To recognize the top performers, we are offering the Marion Star Football Player of Week 2 Poll. Fans may vote as often as allowed for their favorite among the nominees. Voting at MarionStar.com and its app will end at 9 a.m. Tuesday, Sept. 1.
Here are the nominees:
Elgin-Ridgedale in Week 2: Elgin christens its new football field at the expense of a rival
More Week 2 area results: Pleasant, Mount Gilead rebound in Week 2 for football victories
#week #Football #nominees #star
To recognize the top performers, we are offering the Marion Star Football Player of Week 2 Poll. Fans may vote as often as allowed for their favorite among the nominees. Voting at MarionStar.com and its app will end at 9 a.m. Tuesday, Sept. 1.
Here are the nominees:
Elgin-Ridgedale in Week 2: Elgin christens its new football field at the expense of a rival
More Week 2 area results: Pleasant, Mount Gilead rebound in Week 2 for football victories
#week #Football #nominees #star
15 days ago
Gilead Sciences, Inc. (NASDAQ:GILD) delivered its strongest commercial momentum in several years during fiscal Q2 2026, with growth extending across HIV, oncology, and liver disease. Total revenue increased 10% year over year to approximately $7.8 billion, while product sales rose 8% to $7.6 billion.
Yet, the income statement tells a considerably less flattering story. Gilead (NASDAQ:GILD) reported a substantial quarterly loss after recording more than $11 billion in acquired research and development expenses. Investors may look at the earnings as a strengthening commercial business, but not without an expensive attempt to build its next generation of growth.
Gilead's (NASDAQ:GILD) underlying business performed strongly during the quarter. Product sales excluding Veklury increased 10% to $7.6 billion, demonstrating that growth was driven by the company's core portfolio rather than its declining COVID-19 treatment. HIV remained the principal contributor, with sales rising 12% to $5.7 billion. Biktarvy revenue increased 7% to $3.8 billion, while Descovy sales climbed 48% to $967 million. Yeztugo, Gilead's (NASDAQ:GILD) twice-yearly injectable HIV-prevention medicine, generated $232 million as its launch continued to gain traction.
It is significant to note that growth in the quarter was not limited to HIV. Liver-disease sales increased 10% to $877 million, supported primarily by higher demand for Livdelzi and treatments for chronic hepatitis B and hepatitis delta. Livdelzi alone generated $167 million, more than doubling year over year.
Trodelvy also strengthened Gilead's (NASDAQ:GILD) oncology case. Driven by higher demand, sales of the breast-cancer treatment increased 26% to $457 million. Although oncology remains much smaller than HIV, Trodelvy's growth provides evidence that Gilead (NASDAQ:GILD) is developing another meaningful commercial franchise. Management responded to the quarter by raising the lower end of its 2026 product-sales guidance. The company now expects 30.1–30.4 billion, compared with 30.0–30.4 billion previously. It also increased its product-sales forecast excluding Veklury to 29.8–30.1 billion, up from 29.4–29.8 billion.
#gild #increased
Yet, the income statement tells a considerably less flattering story. Gilead (NASDAQ:GILD) reported a substantial quarterly loss after recording more than $11 billion in acquired research and development expenses. Investors may look at the earnings as a strengthening commercial business, but not without an expensive attempt to build its next generation of growth.
Gilead's (NASDAQ:GILD) underlying business performed strongly during the quarter. Product sales excluding Veklury increased 10% to $7.6 billion, demonstrating that growth was driven by the company's core portfolio rather than its declining COVID-19 treatment. HIV remained the principal contributor, with sales rising 12% to $5.7 billion. Biktarvy revenue increased 7% to $3.8 billion, while Descovy sales climbed 48% to $967 million. Yeztugo, Gilead's (NASDAQ:GILD) twice-yearly injectable HIV-prevention medicine, generated $232 million as its launch continued to gain traction.
It is significant to note that growth in the quarter was not limited to HIV. Liver-disease sales increased 10% to $877 million, supported primarily by higher demand for Livdelzi and treatments for chronic hepatitis B and hepatitis delta. Livdelzi alone generated $167 million, more than doubling year over year.
Trodelvy also strengthened Gilead's (NASDAQ:GILD) oncology case. Driven by higher demand, sales of the breast-cancer treatment increased 26% to $457 million. Although oncology remains much smaller than HIV, Trodelvy's growth provides evidence that Gilead (NASDAQ:GILD) is developing another meaningful commercial franchise. Management responded to the quarter by raising the lower end of its 2026 product-sales guidance. The company now expects 30.1–30.4 billion, compared with 30.0–30.4 billion previously. It also increased its product-sales forecast excluding Veklury to 29.8–30.1 billion, up from 29.4–29.8 billion.
#gild #increased
15 days ago
The next few years will test whether Pfizer Inc. (NYSE:PFE) can replace yesterday's blockbusters, and whether Gilead Sciences, Inc. (NASDAQ:GILD) can become more than an HIV company. Pfizer's (NYSE:PFE) newer medicines are gaining traction, but that growth has yet to accelerate the wider business. Gilead (NASDAQ:GILD) is expanding faster, although its performance remains concentrated in one therapeutic area. For investors, this is ultimately a choice between an unfinished turnaround and a stronger growth story still searching for greater breadth.
Pfizer's (NYSE:PFE) strongest result was the performance of its non-COVID portfolio. Revenue excluding Comirnaty and Paxlovid grew 5% operationally, while launched and acquired products generated $3.2 billion and increased 18% operationally. Growth also came from several franchises. Padcev revenue rose 23% operationally to $667 million, supported by increased market share in bladder cancer. The Vyndaqel family generated $1.76 billion, up 8% operationally, while Lorbrena grew 37% operationally. These products give Pfizer more than one avenue for rebuilding revenue as COVID-related demand declines.
Pfizer (NYSE:PFE) lowered its 2026 COVID-product forecast from approximately $5 billion to $4 billion after low infection levels weighed on Paxlovid utilization. Nevertheless, stronger-than-expected non-COVID sales allowed the company to raise the midpoint of its total revenue guidance by $500 million. Cost reductions provide additional support for the company. Pfizer (NYSE:PFE) expects approximately $6.7 billion in savings from its cost-realignment program through 2029. A separate manufacturing-optimization program is expected to generate another $3 billion, bringing anticipated savings across the two programs to approximately $9.7 billion. This leaner cost base could help Pfizer (NYSE:PFE) preserve margins and continue investing in areas such as oncology and obesity.
Gilead (NASDAQ:GILD), however, is currently delivering much stronger underlying growth. Product sales excluding Veklury increased 10% to $7.6 billion, and HIV sales rose 12% to $5.7 billion, with Biktarvy revenue increasing 7% to $3.8 billion and Descovy sales climbing 48% to $967 million. Yeztugo, Gilead's (NASDAQ:GILD) twice-yearly injectable HIV-prevention medicine, contributed $232 million as its launch gained momentum. The product adds a potentially important growth driver to an already dominant HIV portfolio.
Growth, however, was not confined to HIV alone, as liver-disease sales increased 10% to $877 million, while Livdelzi revenue more than doubled from $78 million to $167 million. Trodelvy sales rose 26% to $457 million, providing further evidence that Gilead (NASDAQ:GILD) is building a meaningful oncology franchise. Management subsequently raised its 2026 product-sales outlook to $30.1–$30.4 billion and increased guidance for product sales excluding Veklury to $29.8–$30.1 billion.
#NYSE #million #gild
Pfizer's (NYSE:PFE) strongest result was the performance of its non-COVID portfolio. Revenue excluding Comirnaty and Paxlovid grew 5% operationally, while launched and acquired products generated $3.2 billion and increased 18% operationally. Growth also came from several franchises. Padcev revenue rose 23% operationally to $667 million, supported by increased market share in bladder cancer. The Vyndaqel family generated $1.76 billion, up 8% operationally, while Lorbrena grew 37% operationally. These products give Pfizer more than one avenue for rebuilding revenue as COVID-related demand declines.
Pfizer (NYSE:PFE) lowered its 2026 COVID-product forecast from approximately $5 billion to $4 billion after low infection levels weighed on Paxlovid utilization. Nevertheless, stronger-than-expected non-COVID sales allowed the company to raise the midpoint of its total revenue guidance by $500 million. Cost reductions provide additional support for the company. Pfizer (NYSE:PFE) expects approximately $6.7 billion in savings from its cost-realignment program through 2029. A separate manufacturing-optimization program is expected to generate another $3 billion, bringing anticipated savings across the two programs to approximately $9.7 billion. This leaner cost base could help Pfizer (NYSE:PFE) preserve margins and continue investing in areas such as oncology and obesity.
Gilead (NASDAQ:GILD), however, is currently delivering much stronger underlying growth. Product sales excluding Veklury increased 10% to $7.6 billion, and HIV sales rose 12% to $5.7 billion, with Biktarvy revenue increasing 7% to $3.8 billion and Descovy sales climbing 48% to $967 million. Yeztugo, Gilead's (NASDAQ:GILD) twice-yearly injectable HIV-prevention medicine, contributed $232 million as its launch gained momentum. The product adds a potentially important growth driver to an already dominant HIV portfolio.
Growth, however, was not confined to HIV alone, as liver-disease sales increased 10% to $877 million, while Livdelzi revenue more than doubled from $78 million to $167 million. Trodelvy sales rose 26% to $457 million, providing further evidence that Gilead (NASDAQ:GILD) is building a meaningful oncology franchise. Management subsequently raised its 2026 product-sales outlook to $30.1–$30.4 billion and increased guidance for product sales excluding Veklury to $29.8–$30.1 billion.
#NYSE #million #gild
16 days ago
Gilead Sciences, Inc. (NASDAQ:GILD) delivered its strongest commercial momentum in several years during fiscal Q2 2026, with growth extending across HIV, oncology, and liver disease. Total revenue increased 10% year over year to approximately $7.8 billion, while product sales rose 8% to $7.6 billion.
Yet, the income statement tells a considerably less flattering story. Gilead (NASDAQ:GILD) reported a substantial quarterly loss after recording more than $11 billion in acquired research and development expenses. Investors may look at the earnings as a strengthening commercial business, but not without an expensive attempt to build its next generation of growth.
Gilead's (NASDAQ:GILD) underlying business performed strongly during the quarter. Product sales excluding Veklury increased 10% to $7.6 billion, demonstrating that growth was driven by the company's core portfolio rather than its declining COVID-19 treatment. HIV remained the principal contributor, with sales rising 12% to $5.7 billion. Biktarvy revenue increased 7% to $3.8 billion, while Descovy sales climbed 48% to $967 million. Yeztugo, Gilead's (NASDAQ:GILD) twice-yearly injectable HIV-prevention medicine, generated $232 million as its launch continued to gain traction.
It is significant to note that growth in the quarter was not limited to HIV. Liver-disease sales increased 10% to $877 million, supported primarily by higher demand for Livdelzi and treatments for chronic hepatitis B and hepatitis delta. Livdelzi alone generated $167 million, more than doubling year over year.
Trodelvy also strengthened Gilead's (NASDAQ:GILD) oncology case. Driven by higher demand, sales of the breast-cancer treatment increased 26% to $457 million. Although oncology remains much smaller than HIV, Trodelvy's growth provides evidence that Gilead (NASDAQ:GILD) is developing another meaningful commercial franchise. Management responded to the quarter by raising the lower end of its 2026 product-sales guidance. The company now expects 30.1–30.4 billion, compared with 30.0–30.4 billion previously. It also increased its product-sales forecast excluding Veklury to 29.8–30.1 billion, up from 29.4–29.8 billion.
#product
Yet, the income statement tells a considerably less flattering story. Gilead (NASDAQ:GILD) reported a substantial quarterly loss after recording more than $11 billion in acquired research and development expenses. Investors may look at the earnings as a strengthening commercial business, but not without an expensive attempt to build its next generation of growth.
Gilead's (NASDAQ:GILD) underlying business performed strongly during the quarter. Product sales excluding Veklury increased 10% to $7.6 billion, demonstrating that growth was driven by the company's core portfolio rather than its declining COVID-19 treatment. HIV remained the principal contributor, with sales rising 12% to $5.7 billion. Biktarvy revenue increased 7% to $3.8 billion, while Descovy sales climbed 48% to $967 million. Yeztugo, Gilead's (NASDAQ:GILD) twice-yearly injectable HIV-prevention medicine, generated $232 million as its launch continued to gain traction.
It is significant to note that growth in the quarter was not limited to HIV. Liver-disease sales increased 10% to $877 million, supported primarily by higher demand for Livdelzi and treatments for chronic hepatitis B and hepatitis delta. Livdelzi alone generated $167 million, more than doubling year over year.
Trodelvy also strengthened Gilead's (NASDAQ:GILD) oncology case. Driven by higher demand, sales of the breast-cancer treatment increased 26% to $457 million. Although oncology remains much smaller than HIV, Trodelvy's growth provides evidence that Gilead (NASDAQ:GILD) is developing another meaningful commercial franchise. Management responded to the quarter by raising the lower end of its 2026 product-sales guidance. The company now expects 30.1–30.4 billion, compared with 30.0–30.4 billion previously. It also increased its product-sales forecast excluding Veklury to 29.8–30.1 billion, up from 29.4–29.8 billion.
#product
25 days ago
Two biopharma giants, Merck & Co., Inc. (NYSE:MRK) and Gilead Sciences, Inc. (NASDAQ:GILD), are proving that in modern drug development, the biggest catalyst isn't always competing head-to-head; it is knowing when to join forces. While both companies reported their first-quarter 2026 earnings earlier this year, their recent double dose of clinical and regulatory breakthroughs across oncology and virology shows how strategic alliances can reshape two massive therapeutic markets at once.
Merck & Co., Inc. delivered $16.3 billion in total sales for the first quarter of 2026, up 5% year-over-year (3% excluding foreign exchange). Top-line growth continued to be anchored by its flagship oncology therapy, Keytruda, which, alongside its sub-formulations, brought in $8.0 billion in sales, representing an 8% ex-exchange increase. Pulmonary arterial hypertension treatment Winrevair also contributed strongly with $525 million in quarterly revenue, up 87% ex-exchange. GAAP and non-GAAP bottom-line metrics reflected net losses per share of $1.72 and $1.28, respectively, largely driven by upfront charges tied to the strategic acquisition of Cidara Therapeutics. Despite those acquisition-related charges, Merck narrowed and raised the midpoint of its full-year worldwide sales guidance to between $65.8 billion and $67.0 billion.
Merck's growth story remains heavily reliant on expanding Keytruda's reach into earlier-stage treatments and novel combination regimens. With key patent expirations approaching toward the end of the decade, management has aggressively pursued business development and combination therapies to diversify its revenue base and maintain its dominance in immuno-oncology.
Gilead Sciences, Inc. reported $7.0 billion in total revenue for the first quarter of 2026, posting 5% year-over-year product sales growth. Gilead's base business, excluding COVID-19 treatment Veklury, rose 8% year-over-year to $6.8 billion, powered by its market-leading HIV franchise, which generated $5.0 billion in sales (up 10% year-over-year). Biktarvy remained the primary growth driver, while newly launched therapies like Yeztugo (lenacapavir) for HIV pre-exposure prophylaxis provided fresh momentum. The corporation's adjusted diluted earnings per share reached $2.03.
Backed by strong demand across its core virology portfolio, Gilead Sciences, Inc. raised its full-year 2026 total product sales guidance range by $400 million, targeting $30.0 billion to $30.4 billion.
#billion #merck #sciences #oncology
Merck & Co., Inc. delivered $16.3 billion in total sales for the first quarter of 2026, up 5% year-over-year (3% excluding foreign exchange). Top-line growth continued to be anchored by its flagship oncology therapy, Keytruda, which, alongside its sub-formulations, brought in $8.0 billion in sales, representing an 8% ex-exchange increase. Pulmonary arterial hypertension treatment Winrevair also contributed strongly with $525 million in quarterly revenue, up 87% ex-exchange. GAAP and non-GAAP bottom-line metrics reflected net losses per share of $1.72 and $1.28, respectively, largely driven by upfront charges tied to the strategic acquisition of Cidara Therapeutics. Despite those acquisition-related charges, Merck narrowed and raised the midpoint of its full-year worldwide sales guidance to between $65.8 billion and $67.0 billion.
Merck's growth story remains heavily reliant on expanding Keytruda's reach into earlier-stage treatments and novel combination regimens. With key patent expirations approaching toward the end of the decade, management has aggressively pursued business development and combination therapies to diversify its revenue base and maintain its dominance in immuno-oncology.
Gilead Sciences, Inc. reported $7.0 billion in total revenue for the first quarter of 2026, posting 5% year-over-year product sales growth. Gilead's base business, excluding COVID-19 treatment Veklury, rose 8% year-over-year to $6.8 billion, powered by its market-leading HIV franchise, which generated $5.0 billion in sales (up 10% year-over-year). Biktarvy remained the primary growth driver, while newly launched therapies like Yeztugo (lenacapavir) for HIV pre-exposure prophylaxis provided fresh momentum. The corporation's adjusted diluted earnings per share reached $2.03.
Backed by strong demand across its core virology portfolio, Gilead Sciences, Inc. raised its full-year 2026 total product sales guidance range by $400 million, targeting $30.0 billion to $30.4 billion.
#billion #merck #sciences #oncology
1 month ago
Baron Capital, an investment management company, released its Q2 2026 investor letter for the "Baron Health Care Fund". A copy of the letter is available to download here. The Fund gained 11.99% during the quarter, compared with the 10.48% gain for the Russell 3000 Health Care Index and the 15.44% gain for the Russell 3000 Index. Since inception, the Fund appreciated 10.61% on an annualized basis, compared with 10.02% for the Benchmark and 14.83% for the Index. Strong stock selection in pharmaceuticals, biotechnology, health care equipment, and life sciences tools and services supported the Fund's outperformance, although limited exposure to managed care stocks reduced relative returns. The Fund remains positive on health care due to improving biotechnology funding, strong acquisition activity, recovering managed care margins, and growth from an aging population, chronic disease, medical innovation, and higher health care spending. In addition, please check the Fund's top five holdings to know the best picks in 2026.
In its second-quarter 2026 investor letter, Baron Health Care Fund highlighted Gilead Sciences, Inc. (NASDAQ:GILD). Gilead Sciences, Inc. (NASDAQ:GILD), a biopharmaceutical company that discovers, develops, and commercializes medicines for unmet medical needs, detracted from the fund's performance during the quarter. On August 03, 2026, Gilead Sciences, Inc. (NASDAQ:GILD) closed at $131.15 per share. The one-month return of Gilead Sciences, Inc. (NASDAQ:GILD) was -3.82%, and its shares gained 16.62% over the past 52 weeks. Gilead Sciences, Inc. (NASDAQ:GILD) has a market capitalization of $162.83 billion.
Baron Health Care Fund stated the following regarding Gilead Sciences, Inc. (NASDAQ:GILD) in its Q2 2026 investor letter:
"Biotechnology company Gilead Sciences, Inc. (NASDAQ:GILD) is best known for developing and commercializing therapies that treat and prevent HIV. Following a strong first-quarter advance driven by continued enthusiasm surrounding the launch of Yeztugo for HIV prevention, the stock detracted from performance in the second quarter. Shares pulled back after management issued conservative 2026 guidance in February, including expectations for approximately $800 million of Yeztugo sales, below investor expectations. Despite the more cautious outlook, we remain confident in Yeztugo's long-term opportunity. Unlike Descovy, a daily oral preventive treatment, Yeztugo is a twice-yearly injectable therapy that has the potential to significantly improve patient compliance. Looking ahead, we continue to view Gilead as a leader in HIV treatment and prevention, with Yeztugo representing an important new preventive option and a promising next-generation pipeline that includes a weekly oral lenacapavir and islatravir combination being developed with Merck & Co., Inc., as well as a wholly-owned weekly regimen incorporating a novel integrase inhibitor designed to offer a higher barrier to resistance."
#sciences #gild #Health
In its second-quarter 2026 investor letter, Baron Health Care Fund highlighted Gilead Sciences, Inc. (NASDAQ:GILD). Gilead Sciences, Inc. (NASDAQ:GILD), a biopharmaceutical company that discovers, develops, and commercializes medicines for unmet medical needs, detracted from the fund's performance during the quarter. On August 03, 2026, Gilead Sciences, Inc. (NASDAQ:GILD) closed at $131.15 per share. The one-month return of Gilead Sciences, Inc. (NASDAQ:GILD) was -3.82%, and its shares gained 16.62% over the past 52 weeks. Gilead Sciences, Inc. (NASDAQ:GILD) has a market capitalization of $162.83 billion.
Baron Health Care Fund stated the following regarding Gilead Sciences, Inc. (NASDAQ:GILD) in its Q2 2026 investor letter:
"Biotechnology company Gilead Sciences, Inc. (NASDAQ:GILD) is best known for developing and commercializing therapies that treat and prevent HIV. Following a strong first-quarter advance driven by continued enthusiasm surrounding the launch of Yeztugo for HIV prevention, the stock detracted from performance in the second quarter. Shares pulled back after management issued conservative 2026 guidance in February, including expectations for approximately $800 million of Yeztugo sales, below investor expectations. Despite the more cautious outlook, we remain confident in Yeztugo's long-term opportunity. Unlike Descovy, a daily oral preventive treatment, Yeztugo is a twice-yearly injectable therapy that has the potential to significantly improve patient compliance. Looking ahead, we continue to view Gilead as a leader in HIV treatment and prevention, with Yeztugo representing an important new preventive option and a promising next-generation pipeline that includes a weekly oral lenacapavir and islatravir combination being developed with Merck & Co., Inc., as well as a wholly-owned weekly regimen incorporating a novel integrase inhibitor designed to offer a higher barrier to resistance."
#sciences #gild #Health
2 months ago
Gilead Sciences, Inc. (GILD), headquartered in Foster City, California, is a biopharmaceutical company that discovers, develops, and commercializes medicines in the areas of unmet medical need. Valued at $166.7 billion by market cap, the company's primary areas of focus include HIV, AIDS, liver disease, and serious cardiovascular and respiratory conditions. The HIV giant is expected to announce its fiscal second-quarter earnings for 2026 in the near term.
Ahead of the event, ******* ysts expect GILD to report a loss of $7.09 per share on a diluted basis, down 452.7% from a profit of $2.01 per share in the year-ago quarter. The company has consistently surpassed the consensus estimates in each of the last four quarters.
Huge, Unusual Intel Options Volume Today Ahead of Earnings This Week
Intel Stock Is Down, But Put Premiums are High - Put Short Sellers Love the High Yields
The Number Tesla Stock Bulls Are Really Waiting for This Earnings Season Has Nothing to Do With Cars
#earnings
Ahead of the event, ******* ysts expect GILD to report a loss of $7.09 per share on a diluted basis, down 452.7% from a profit of $2.01 per share in the year-ago quarter. The company has consistently surpassed the consensus estimates in each of the last four quarters.
Huge, Unusual Intel Options Volume Today Ahead of Earnings This Week
Intel Stock Is Down, But Put Premiums are High - Put Short Sellers Love the High Yields
The Number Tesla Stock Bulls Are Really Waiting for This Earnings Season Has Nothing to Do With Cars
#earnings
2 months ago
Here is the week-by-week 2026 schedule for central Ohio high school football. Schedules were obtained from area schools and are subject to change.
Fairbanks at North Robinson Colonel Crawford; Harvest Prep at Versailles
Africentric at Groveport; Amanda-Clearcreek at West Jefferson; Bellville Clear Fork at Granville; Berlin Center Western Reserve at Whetstone; Berne Union at Bidwell River Valley; Bloom-Carroll at Caledonia River Valley; Bucyrus Wynford at Cardington; Canal Winchester at Grove City; Centennial at Grandview Heights; Centerburg at Utica; Chillicothe Southeastern at Fairfield Christian; Circleville at Chillicothe; Dalton at Danville; Dayton Dunbar at Briggs; Delaware at Buckeye Valley; Dublin Coffman at Hartley; Dublin Scioto at Thomas Worthington; East Knox at Northridge; Eastmoor Academy vs. Ready at Fortress Obetz; Fisher Catholic at Belpre; Franklin Heights at West; Fredericktown at Highland; Hamilton Township at Whitehall; Heath at Duncan Falls Philo; Hilliard Bradley at Big Walnut; Hilliard Darby at Lancaster; Huntington at Newark Catholic; KIPP Columbus at Beechcroft; Liberty Union at Woodsfield Monroe Central; Licking Heights at Newark; Linden-McKinley at Bexley; Logan Elm at Chillicothe Zane Trace; Madison-Plains at Westfall; Mansfield Senior at Hilliard Davidson; Marion Pleasant at North Union; Martins Ferry at Mount Gilead; Marysville at Westerville North; Millersport at Portsmouth Sciotoville East; Mount Vernon at Marion Harding; New Albany at London; New Lexington at Fairfield Union; Northland at Columbus Academy; Olentangy Liberty vs. Lakewood St. Edward at Lakewood; Olentangy Orange at Olentangy Berlin; Pickerington Central at Gahanna; Pickerington North at Troy; Reynoldsburg at Toledo Whitmer; St. Charles at Central Crossing; South at Mifflin; Thornville Sheridan at Licking Valley; Upper Arlington at Olentangy; Vermilion at Johnstown; Walnut Ridge at East; Watkins Memorial at Worthington Kilbourne; Watterson at Whitehouse Anthony Wayne; West Liberty-Salem at Jonathan Alder; Westerville Central at Marion-Franklin; Westerville South at Dublin Jerome; Westland at Teays Valley; Worthington Christian at Grove City Christian; Youngstown Ursuline at DeSales; Zanesville West Muskingum at Lakewood
Independence vs. Dayton Meadowdale at Welcome Stadium; Columbus Crusaders at Byron Center (Michigan) Grand Valley Christian
Beechcroft at Independence; Berne Union at Chillicothe Huntington; Bexley at Worthington Christian; Big Walnut at Dublin Coffman; Briggs at Dublin Scioto; Buckeye Valley at Africentric; Bucyrus Wynford at East Knox; Canal Winchester at New Albany; Cardington at Sycamore Mohawk; Centerburg at Johnstown; Cincinnati Aiken at Northland; Circleville at Washington Court House; Cleveland Glenville at Olentangy Liberty; Cleveland St. Ignatius at Pickerington North; Danville at Utica; DeSales at Walnut Ridge; East at Whitehall; Eastmoor Academy at Cincinnati College Preparatory Academy; Franklin Heights at Linden-McKi
Fairbanks at North Robinson Colonel Crawford; Harvest Prep at Versailles
Africentric at Groveport; Amanda-Clearcreek at West Jefferson; Bellville Clear Fork at Granville; Berlin Center Western Reserve at Whetstone; Berne Union at Bidwell River Valley; Bloom-Carroll at Caledonia River Valley; Bucyrus Wynford at Cardington; Canal Winchester at Grove City; Centennial at Grandview Heights; Centerburg at Utica; Chillicothe Southeastern at Fairfield Christian; Circleville at Chillicothe; Dalton at Danville; Dayton Dunbar at Briggs; Delaware at Buckeye Valley; Dublin Coffman at Hartley; Dublin Scioto at Thomas Worthington; East Knox at Northridge; Eastmoor Academy vs. Ready at Fortress Obetz; Fisher Catholic at Belpre; Franklin Heights at West; Fredericktown at Highland; Hamilton Township at Whitehall; Heath at Duncan Falls Philo; Hilliard Bradley at Big Walnut; Hilliard Darby at Lancaster; Huntington at Newark Catholic; KIPP Columbus at Beechcroft; Liberty Union at Woodsfield Monroe Central; Licking Heights at Newark; Linden-McKinley at Bexley; Logan Elm at Chillicothe Zane Trace; Madison-Plains at Westfall; Mansfield Senior at Hilliard Davidson; Marion Pleasant at North Union; Martins Ferry at Mount Gilead; Marysville at Westerville North; Millersport at Portsmouth Sciotoville East; Mount Vernon at Marion Harding; New Albany at London; New Lexington at Fairfield Union; Northland at Columbus Academy; Olentangy Liberty vs. Lakewood St. Edward at Lakewood; Olentangy Orange at Olentangy Berlin; Pickerington Central at Gahanna; Pickerington North at Troy; Reynoldsburg at Toledo Whitmer; St. Charles at Central Crossing; South at Mifflin; Thornville Sheridan at Licking Valley; Upper Arlington at Olentangy; Vermilion at Johnstown; Walnut Ridge at East; Watkins Memorial at Worthington Kilbourne; Watterson at Whitehouse Anthony Wayne; West Liberty-Salem at Jonathan Alder; Westerville Central at Marion-Franklin; Westerville South at Dublin Jerome; Westland at Teays Valley; Worthington Christian at Grove City Christian; Youngstown Ursuline at DeSales; Zanesville West Muskingum at Lakewood
Independence vs. Dayton Meadowdale at Welcome Stadium; Columbus Crusaders at Byron Center (Michigan) Grand Valley Christian
Beechcroft at Independence; Berne Union at Chillicothe Huntington; Bexley at Worthington Christian; Big Walnut at Dublin Coffman; Briggs at Dublin Scioto; Buckeye Valley at Africentric; Bucyrus Wynford at East Knox; Canal Winchester at New Albany; Cardington at Sycamore Mohawk; Centerburg at Johnstown; Cincinnati Aiken at Northland; Circleville at Washington Court House; Cleveland Glenville at Olentangy Liberty; Cleveland St. Ignatius at Pickerington North; Danville at Utica; DeSales at Walnut Ridge; East at Whitehall; Eastmoor Academy at Cincinnati College Preparatory Academy; Franklin Heights at Linden-McKi
3 months ago
Lukas Gage shares how a lack of ****** ual health education growing up led to embarrassment and hesitation
He discusses contracting two STIs in a past relationship and how it motivated him to prioritize ****** ual health
Gage partners with Gilead's HealthySexual campaign to promote stigma-free conversations
Lukas Gage has no problem talking about his ****** ual health, but it took a while to get to that point.
The 31-year-old actor — known for roles in The White Lotus, You and Euphoria — recently opened up to PEOPLE about the growth he's had in his ****** ual health journey and admitted that he wasn't taught much about it growing up.
He discusses contracting two STIs in a past relationship and how it motivated him to prioritize ****** ual health
Gage partners with Gilead's HealthySexual campaign to promote stigma-free conversations
Lukas Gage has no problem talking about his ****** ual health, but it took a while to get to that point.
The 31-year-old actor — known for roles in The White Lotus, You and Euphoria — recently opened up to PEOPLE about the growth he's had in his ****** ual health journey and admitted that he wasn't taught much about it growing up.
3 months ago
Is GILD a good stock to buy? We came across a bullish thesis on Gilead Sciences, Inc. on r/investing_discussion by Variant_Invest. In this article, we will summarize the bulls’ thesis on GILD. Gilead Sciences, Inc.'s share was trading at $133.73 as of May 26th. GILD’s trailing and forward P/E were 18.19 and 15.22 respectively according to Yahoo Finance.
Pressmaster/Shutterstock.com
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States and internationally. GILD is being mischaracterized by the market as a slow-growth HIV cash cow despite a rapidly shifting pipeline that increasingly skews toward long-acting HIV innovation and a credible oncology expansion, suggesting the current valuation underappreciates its multi-platform earnings durability.
Read More: 15 AI Stocks That Are Quietly Making Investors Rich
Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential
Pressmaster/Shutterstock.com
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States and internationally. GILD is being mischaracterized by the market as a slow-growth HIV cash cow despite a rapidly shifting pipeline that increasingly skews toward long-acting HIV innovation and a credible oncology expansion, suggesting the current valuation underappreciates its multi-platform earnings durability.
Read More: 15 AI Stocks That Are Quietly Making Investors Rich
Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential
3 months ago
Is GILD a good stock to buy? We came across a bullish thesis on Gilead Sciences, Inc. on r/investing_discussion by Variant_Invest. In this article, we will summarize the bulls' thesis on GILD. Gilead Sciences, Inc.'s share was trading at $133.73 as of May 26th. GILD's trailing and forward P/E were 18.19 and 15.22 respectively according to Yahoo Finance.
Pressmaster/Shutterstock.com
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States and internationally. GILD is being mischaracterized by the market as a slow-growth HIV cash cow despite a rapidly shifting pipeline that increasingly skews toward long-acting HIV innovation and a credible oncology expansion, suggesting the current valuation underappreciates its multi-platform earnings durability.
Read More: 15 AI Stocks That Are Quietly Making Investors Rich
Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential
Pressmaster/Shutterstock.com
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States and internationally. GILD is being mischaracterized by the market as a slow-growth HIV cash cow despite a rapidly shifting pipeline that increasingly skews toward long-acting HIV innovation and a credible oncology expansion, suggesting the current valuation underappreciates its multi-platform earnings durability.
Read More: 15 AI Stocks That Are Quietly Making Investors Rich
Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential
3 months ago
Gilead Sciences, Inc. (NASDAQ:GILD) is one of the best inexpensive stocks to invest in right now. Gilead Sciences, Inc. (NASDAQ:GILD) announced on May 27 new results from a post hoc ***** ysis that showed that Livdelzi® was ***** ociated with high and sustained rates of normalization of a key liver marker in people living with primary biliary cholangitis. The company reported that participants with increased ALP levels in an ongoing Phase 3 study experienced reductions in ALP after treatment, and the data showcase the potential role of Livdelzi in people with PBC who continually have elevated ALP despite prior treatment with first-line therapy.
Gilead Sciences, Inc. (NASDAQ:GILD) stated that the findings are “highly relevant” for people living with PBC with inadequately controlled disease based on elevated ALP levels, as that is a population that is historically underrepresented in randomized clinical trials. The company would present the data at the European ***** ociation for the Study of the Liver (EASL) Congress 2026, held May 27–30 in Barcelona, Spain.
Gilead Sciences, Inc. (NASDAQ:GILD) is a biotech company that advances medicines to prevent and treat serious diseases such as cancer, immunodeficiency virus (HIV), viral hepatitis, and COVID-19. Its portfolio of drugs focuses on medical areas with unmet needs and includes AmBisome, Atripla, Biktarvy, Cayston, Complera, and others.
While we acknowledge the potential of GILD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.
Gilead Sciences, Inc. (NASDAQ:GILD) stated that the findings are “highly relevant” for people living with PBC with inadequately controlled disease based on elevated ALP levels, as that is a population that is historically underrepresented in randomized clinical trials. The company would present the data at the European ***** ociation for the Study of the Liver (EASL) Congress 2026, held May 27–30 in Barcelona, Spain.
Gilead Sciences, Inc. (NASDAQ:GILD) is a biotech company that advances medicines to prevent and treat serious diseases such as cancer, immunodeficiency virus (HIV), viral hepatitis, and COVID-19. Its portfolio of drugs focuses on medical areas with unmet needs and includes AmBisome, Atripla, Biktarvy, Cayston, Complera, and others.
While we acknowledge the potential of GILD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.
3 months ago
We recently compiled a list of the 11 Most Undervalued Pharma Stocks to Invest In. Gilead Sciences, Inc. (NASDAQ:GILD) is one of the most undervalued stocks to invest in.
TheFly reported on May 27 that GILD presented long-term interim findings from the ongoing Phase 3 ***** URE study of Livdelzi at the 2026 European ***** ociation for the Study of the Liver Congress in Barcelona. A post hoc ***** ysis showed sustained improvement in liver function markers among patients with primary biliary cholangitis who had persistently elevated alkaline phosphatase despite prior first-line therapy.
Across treated participants, ALP levels declined, and a high proportion achieved biochemical normalization over extended follow-up, with durable responses observed up to two years. Additional ***** yses indicated stability in other indicators of cholestasis and liver stiffness over time. The safety profile remained consistent with earlier findings, with no treatment discontinuations due to adverse events and no new safety concerns identified.
In an interconnected pipeline development, Gilead Sciences, Inc. (NASDAQ:GILD) announced on May 22 that the European Medicines Agency’s CHMP issued a positive opinion recommending marketing authorization for Trodelvy (sacituzumab govitecan-hziy) as a first-line monotherapy option for adult patients with unresectable locally advanced or metastatic triple-negative breast cancer who are not eligible for PD-1 or PD-L1 inhibitor therapy.
The decision is based on Phase 3 ASCENT-03 results demonstrating statistically significant and clinically meaningful improvement in progression-free survival compared with standard chemotherapy, including a 38% reduction in the risk of disease progression or death. Metastatic TNBC remains a highly aggressive cancer with limited first-line options and poor outcomes. The recommendation now proceeds to the European Commission for final review, with a decision expected later in 2026.
TheFly reported on May 27 that GILD presented long-term interim findings from the ongoing Phase 3 ***** URE study of Livdelzi at the 2026 European ***** ociation for the Study of the Liver Congress in Barcelona. A post hoc ***** ysis showed sustained improvement in liver function markers among patients with primary biliary cholangitis who had persistently elevated alkaline phosphatase despite prior first-line therapy.
Across treated participants, ALP levels declined, and a high proportion achieved biochemical normalization over extended follow-up, with durable responses observed up to two years. Additional ***** yses indicated stability in other indicators of cholestasis and liver stiffness over time. The safety profile remained consistent with earlier findings, with no treatment discontinuations due to adverse events and no new safety concerns identified.
In an interconnected pipeline development, Gilead Sciences, Inc. (NASDAQ:GILD) announced on May 22 that the European Medicines Agency’s CHMP issued a positive opinion recommending marketing authorization for Trodelvy (sacituzumab govitecan-hziy) as a first-line monotherapy option for adult patients with unresectable locally advanced or metastatic triple-negative breast cancer who are not eligible for PD-1 or PD-L1 inhibitor therapy.
The decision is based on Phase 3 ASCENT-03 results demonstrating statistically significant and clinically meaningful improvement in progression-free survival compared with standard chemotherapy, including a 38% reduction in the risk of disease progression or death. Metastatic TNBC remains a highly aggressive cancer with limited first-line options and poor outcomes. The recommendation now proceeds to the European Commission for final review, with a decision expected later in 2026.
